New vaccine is tailor-made for intimate dystrophy
Alzheimers disease (AD) is the most common neurodegenerative brain disease in adults affecting 1 in 10000 people. It is a progressive debilitating and incurable brain disease affecting muscles cognition vision speech and movement. Scientists from Charit – Universittsmedizin Berlin have now achieved a successful application of 1 — a new and effective 1-based vaccine candidate for AD. In addition an experimental treatment using this 1-based vaccine was found to reduce the severity of a type of dementia.
A variety of 1-based vaccines are being evaluated to combat AD. Experts from the Department of PaediatricsAdolescence of Charite in Freist Hall of the Max Planck Institute for Biophysics have now demonstrated the safety and efficacy of their 1-based vaccine candidate against AD in ameliorating the signs of an early-onset of AD.
Autophagy is a dynamic process in which pieces of damaged or discarded parts of a cell – for example the mitochondria – are removed and integrated into a new cell and the cell divides normally back into two differentiated forms one with a gene encoding the protein cytochrome P45028. The second form is called PP32.
Autophagy enables cells to divide without the need to express viral transcripts. Deletion of cytochrome P45028 is one of the factors in the progression of AD. Scientists have now shown that the use of a new 1-based 1-based vaccine can reduce the risk of developing AD by 65.
A vaccine that protects by blocking cytochrome P45028.
Keeping cytochrome P45028 (CPP28) inactivated is a promising approach for the treatment of AD. The vaccine was developed using a completely transgenic (AV) rat model. This animal model allows scientists to directly analyze all relevant factors. Reactors and other proteins of infected cells can be detected in injected tissue. This allows prolonging and optimizing the vaccine production. It also allows a larger number of animals to be introduced to the vaccine. Tissue segments of the affected parts that normally are removed during the disease stages for example are now removed during the treatment period. Scientists believe that this will greatly enhance the vaccine effectiveness.
Remarkably that this 1-based vaccine is effective in reducing the testicular hormone inhibiting effect and thus protecting against AD.
Current viral-based vaccines which have mostly been studied in animals have mainly been tested in broad randomised clinical trials. In large-scale randomized testing in multiple diseases humans have been tested only after a specific dose of this new 1-based vaccine is used. Once used with animals the 1-based vaccine is expected to be found at a relatively low dose compared to other common viral-based vaccines.
Professor Hilde Stoelz Head of the Program of Molecular Immunology Immunology at Charits Department of PediatricsAdolescence in Freist Hall of the Max Planck Institute for Biophysics.